{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:53:56Z","timestamp":1790096036963,"version":"4.0.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Cancer therapies are increasingly linked to a wide spectrum of cardiovascular toxicities, presenting significant challenges in the long-term care of oncology patients. Among these, therapy-induced hypertension stands out as one of the most consistent and clinically relevant adverse effects, especially with agents targeting the VEGF pathway. Understanding the mechanisms behind this form of hypertension is critical, as it not only represents a modifiable cardiovascular risk factor but may also serve as a biomarker of therapeutic efficacy in certain cancer treatments. Clinical evidence underscores the importance of early detection and aggressive blood pressure control to improve both cardiovascular and oncologic outcomes. The most well-characterized and clinically significant subtype of therapy-related hypertension is that induced by VEGF pathway inhibitors, owing to its high incidence, rapid onset, and well-defined mechanistic basis. In this review, we specifically examine VEGFi-associated hypertension as a prototypical model of onco-hypertension. Evidence-based strategies for managing therapy-induced hypertension emphasize early detection and individualized treatment plans. Renin-angiotensin system inhibitors (RAAS inhibitors) are frequently recommended as first-line agents due to their favorable cardiovascular profile and potential synergistic effects with some cancer therapies. Calcium-channel blockers (CCBs) also demonstrate strong efficacy and are often used in combination regimens to achieve optimal blood pressure control. Successful management requires a multidisciplinary approach, integrating expertise from oncology, cardiology, and primary care. Proactive surveillance, patient education, and risk stratification are essential components of care. As the field of cardio-oncology continues to evolve, structured blood pressure management remains a cornerstone of safe and effective cancer care, ensuring that patients receive optimal therapeutic benefit while minimizing cardiovascular risk.<\/jats:p>","DOI":"10.3389\/fcvm.2026.1748445","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:40:07Z","timestamp":1777351207000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Onco-hypertension: hypertension induced by VEGF pathway inhibition"],"prefix":"10.3389","volume":"13","author":[{"given":"Nicolas L.","family":"Palaskas","sequence":"first","affiliation":[{"name":"Department of Cardiology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Fernanda L\u00f3pez","family":"Moreno","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Casso-Chapa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah I.","family":"Beinart","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nnenne","family":"Nnanna","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keila Carolina Ostos","family":"Mendoza","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Deswal","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Wamique","family":"Yusuf","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstratios","family":"Koutroumpakis","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ichi","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Ewer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41569-020-0347-2","article-title":"Vascular toxic effects of cancer therapies","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/35025220","article-title":"Angiogenesis in cancer and other diseases","volume":"407","author":"Carmeliet","year":"2000","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy","volume":"333","author":"Ferrara","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"B7","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.semnephrol.2010.09.007","article-title":"Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker","volume":"30","author":"Robinson","year":"2010","journal-title":"Semin Nephrol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0002-9440(10)63273-7","article-title":"Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts","volume":"165","author":"Inai","year":"2004","journal-title":"Am J Pathol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jaccao.2019.08.012","article-title":"Increase in blood pressure associated with tyrosine kinase inhibitors targeting vascular endothelial growth factor","volume":"1","author":"Waliany","year":"2019","journal-title":"JACC CardioOncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1016\/j.ekir.2024.03.005","article-title":"Risk factors for severe hypertension and proteinuria after treatment with vascular endothelial growth factor signaling pathway inhibitors among patients with cancer","volume":"9","author":"Hanna","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B11","doi-asserted-by":"publisher","first-page":"616837","DOI":"10.3389\/fimmu.2021.616837","article-title":"Direct and indirect modulation of T cells by VEGF-A counteracted by anti-angiogenic treatment","volume":"12","author":"Bourhis","year":"2021","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1002\/JLB.5RU0222-082R","article-title":"Direct and indirect regulation of the tumor immune microenvironment by VEGF","volume":"111","author":"Zhang","year":"2022","journal-title":"J Leukoc Biol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13045-021-01034-0","article-title":"The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials","volume":"14","author":"Saeed","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1487610","DOI":"10.3389\/fimmu.2024.1487610","article-title":"Leveraging the synergy between anti-angiogenic therapy and immune checkpoint inhibitors to treat digestive system cancers","volume":"15","author":"Xu","year":"2024","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrm1911","article-title":"VEGF Receptor signalling - in control of vascular function","volume":"7","author":"Olsson","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J Exp Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S1470-2045(19)30735-1","article-title":"Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study","volume":"21","author":"Rini","year":"2020","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1056\/NEJMra1106556","article-title":"Focal segmental glomerulosclerosis","volume":"365","author":"D'agati","year":"2011","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/ckj\/sfaa137","article-title":"Changes in blood pressure during treatment with the tyrosine kinase inhibitor lenvatinib","volume":"14","author":"Saito","year":"2021","journal-title":"Clin Kidney J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11912-018-0708-8","article-title":"Tyrosine kinase inhibitor-induced hypertension","volume":"20","author":"Agarwal","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"B25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Group","year":"2015","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ejcsup.2013.07.016","article-title":"Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors","volume":"11","author":"Schmidinger","year":"2013","journal-title":"EJC Suppl"},{"key":"B29","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/annonc\/mdv147","article-title":"Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma","volume":"26","author":"Izzedine","year":"2015","journal-title":"Ann Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1158\/1078-0432.CCR-14-2332","article-title":"Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma","volume":"21","author":"Mckay","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11912-022-01224-0","article-title":"VEGF Receptor inhibitor-induced hypertension: emerging mechanisms and clinical implications","volume":"24","author":"Camarda","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"816897","DOI":"10.4061\/2011\/816897","article-title":"Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers","volume":"2011","author":"Escalante","year":"2011","journal-title":"Cardiol Res Pract"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1161\/CIRCULATIONAHA.115.018347","article-title":"Vascular toxicities of cancer therapies: the old and the new\u2013an evolving avenue","volume":"133","author":"Herrmann","year":"2016","journal-title":"Circulation"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1748445\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:40:12Z","timestamp":1777351212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1748445\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":34,"alternative-id":["10.3389\/fcvm.2026.1748445"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1748445","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"article-number":"1748445"}}